Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Everest Medicines Limited
  6. News
  7. All News
    1952   KYG3224E1061

EVEREST MEDICINES LIMITED

(1952)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about EVEREST MEDICINES LIMITED
01/13Everest Medicines Unit Secures Global License to Products, Tech for Coronavirus Treatme..
MT
01/13Everest Medicines Limited Enters into A Global Licensing Agreement to Develop, Manufact..
CI
01/11Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy in Combi..
AQ
01/10Everest Medicines Will Participate in Clinical Trial with Gilead and Msd to Evaluate Tr..
CI
01/03Everest Medicines Limited Announces Taiwan FDA Has Accepts New Drug Application for Sac..
CI
2021Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vacc..
CI
2021Everest Medicines Limited Announces Acceptance of New Drug Application for Sacituzumab ..
CI
2021Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Stra..
CI
2021Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China..
PR
2021Everest Medicines' Phase 2b Trial in China of Breast Cancer Drug Meets Study Endpoint; ..
MT
2021Everest Medicines Eyes Buyback of Nearly $13 Million Worth of Shares
MT
2021Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program
PR
2021Everest Medicines Announces Share Repurchase Transaction Details
PR
2021Certain Shares of Everest Medicines Limited are subject to a Lock-Up Agreement Ending o..
CI
2021Everest Medicines Limited commences an Equity Buyback Plan for 29,684,786 shares, repre..
CI
2021EVEREST MEDICINES' : New Drug Application for Complicated Intra-Abdominal Infections Treat..
MT
2021Everest Medicines Initiates Submission of New Drug Application in Hong Kong for XeravaT..
CI
2021EVEREST MEDICINES : Initiates Submission of New Drug Application in Hong Kong for XeravaTM..
PR
2021Everest Medicines Limited Business Update on the Submission of New Drug Application in ..
CI
2021EVEREST MEDICINES : Wins Nod to Begin Clinical Trial of Novel Bacterial Infections Treatme..
MT
2021EVEREST MEDICINES : Announces Approval of Investigational New Drug Application by China NM..
PR
2021Everest Medicines Limited Receives Approval for Investigational New Drug Application fo..
CI
2021Health Care Stocks Slightly Higher in Premarket Thursday
MT
2021EVEREST MEDICINES : Strikes R&D Tie-Up with Nasdaq-listed AbCellera Biologics for Therapeu..
MT
2021ABCELLERA BIOLOGICS : Everest Medicines Enter Multi-Year Collaboration, License Agreement
MT
2021EVEREST MEDICINES : Wins License to Kidney Disease Treatment; Shares Rise 4%
MT
2021EVEREST MEDICINES : Providence Therapeutics And Everest Medicines Enter Into Comprehensive..
AQ
2021EVEREST MEDICINES : Sinovent and SinoMab Announce Licensing Agreement for Global Developme..
PR
2021EVEREST MEDICINES : China's Everest Medicines Strikes Vaccine Deal With Canada's Providenc..
MT
2021EVEREST MEDICINES : to bring Canadian biotech's potential COVID shots to China, other mark..
RE
2021EVEREST MEDICINES : Enters into Comprehensive Agreements with Providence Therapeutics to A..
PR
2021Providence Therapeutics Holdings Inc. Enters into Comprehensive Agreements with Everest..
CI
2021EVEREST MEDICINES : Announces Up to HK$100 million Share Repurchase Program
PR
2021EVEREST MEDICINES : Announces Half-Year 2021 Interim Results
PR
2021Everest Medicines Limited Reports Unaudited Consolidated Earnings Results for the Six M..
CI
2021EVEREST MEDICINES : Doses First Patient in China Clinical Trial of Cancer Therapy
MT
2021Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of ..
CI
2021Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Ph..
CI
2021EVEREST MEDICINES : Taiwan to Expedite Review of Everest Medicines' Breast Cancer Drug
MT
2021Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designatio..
CI
2021Everest Medicines Limited Enters into A Strategic Collaboration with MediTrust Health C..
CI
2021EVEREST MEDICINES : Teams Up with Medbanks Health Technology
MT
2021Everest Medicines Announces Strategic Collaboration with Medbanks Health Technology to ..
CI
2021EVEREST MEDICINES : Signs Strategic Commercial Partnership with Tencent
MT
2021EVEREST MEDICINES : Announces Strategic Commercial Partnership with Global Technology Comp..
PR
2021EVEREST MEDICINES' : US Licensing Partner Strikes Deal With Pfizer
MT
2021EVEREST MEDICINES : Grants Nearly 3 Million Share Awards to Employees
MT
2021SPERO THERAPEUTICS : Starts SPR206 Trials in Bronchoalveolar Lavage, Renal Impairment
MT
2021EVEREST MEDICINES : Chinese Regulators Grant Priority Review to Everest Medicines' Cancer ..
MT
2021Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govi..
CI
2021EVEREST MEDICINES : Chinese Regulators Accept Everest Medicines' Biologics License Applica..
MT
2021Everest Medicines announces that the China National Medical Products Administration has..
CI
2021EVEREST MEDICINES : Monthly Return of Equity Issuer on Movements in Securities for the mon..
PU
2021EVEREST MEDICINES : Voluntary announcement business update on receiving orphan drug design..
PU
2021EVEREST MEDICINES' : Breast Cancer Therapy Wins Orphan Drug Designation in South Korea
MT
2021Everest Medicines Limited Receives Orphan Drug Designation from the Ministry of Food an..
CI
2021EVEREST MEDICINES : Form of Proxy for the Annual General Meeting to be held on Tuesday, 1 ..
PU
2021CIRCULAR RE : Proposed Re-election of Directors and Proposed Granting of General Mandates ..
PU
2021Everest Medicines Limited Reports Consolidated Earnings Results for the Year Ended Dece..
CI
2021EVEREST MEDICINES : Appoints Former J&J Exec as Chief Scientific Officer
MT
2021Everest Medicines Partner Wins US FDA's Accelerated Approval for Cancer Drug
MT
2021Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer
CI
2021EVEREST MEDICINES : Voluntary announcement - appointment of chief scientific officer
PU
2021Everest Medicines Announces US FDA Grants Licensing Partner Gilead Sciences, Inc. Accel..
CI
2021EVEREST MEDICINES : Announces that the US FDA has Granted Licensing Partner Gilead Science..
PR
2021EVEREST MEDICINES : Voluntary announcement business update on us fda granting licensing pa..
PU
2021EVEREST MEDICINES : Monthly Return of Equity Issuer on Movements in Securities for the mon..
PU
2021Everest Medicines Shares Jump 4% as Licensing Partner Wins US FDA Nod for Cancer Drug
MT
2021Certain Shares of Everest Medicines Limited are subject to a Lock-Up Agreement Ending o..
CI
2021EVEREST MEDICINES : Announces that Licensing Partner Gilead Sciences, Inc. has Received Fu..
PR
2021EVEREST MEDICINES : Voluntary announcement business update on licensing partner gilead sci..
PU
2021Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evalua..
CI
2021EVEREST MEDICINES : Voluntary announcement business update on china nmpa approval of clini..
PU
2021EVEREST MEDICINES : Announces Financial Results for Full Year Ended December 31, 2020
PR
2021Everest Medicines Reports Earnings Results for the Full Year Ended 31 December 2020
CI
1  2Next
Upcoming event on EVEREST MEDICINES LIMITED
03/21/22